Allergan Unlimited Company, formerly Allergan Limited, is an Ireland-based pharmaceutical company. The Company is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. The Company's products primarily focus on four key therapeutic areas, including medical aesthetics, eye care, central nervous system and gastroenterology.

Employees

Sector

Pharmaceuticals

More about the company

Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI

Market Cap	63.66B 54.53B 51.02B 46.71B 87.65B 6,091B 88.81B 603B 235B 3,060B 239B 234B 10,120B	P/E 2018	-8.76x	P/E 2019	-11.9x
Enterprise Value	80.96B 69.35B 64.89B 59.4B 111B 7,747B 113B 767B 299B 3,891B 304B 297B 12,871B	EV / Sales 2018	4.24x	EV / Sales 2019	4.98x
Free-Float	99.9%	Yield 2018	2.15%	Yield 2019	1.55%

Apr. 07	Allergan Aesthetics Opens New Ami Training Center in Austin	CI
Mar. 31	Allergan Aesthetics Announces Fourth Annual CoolMonth With Deals On CoolSculpting	CI
Mar. 30	Allergan Aesthetics Presents Findings on Safety and Efficacy of Repeat Trenibote Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors At the 2026 American Academy of Dermatology Meeting	CI
Mar. 19	Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions	CI
Mar. 04	Allergan Aesthetics Shares Medical Weight Loss Data and the Changing Profile of Patients	CI
Nov. 12	Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence	CI
25-09-25	AllAllergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality At AMWC Dubai	CI
25-08-19	Allergan Aesthetics Unveils Its Newest Hydration Hero	CI
25-06-30	U.S. Food and Drug Administration Accepts for Review Allergan Aesthetics Premarket Approval Application for Skinvive by Juvederm for the Improvement of Neck Appearance	CI
25-02-12	Allergan Aesthetics to Launch Three New Training Centers in the U.S. Expanding Access to High Quality Aesthetics Training	CI
24-10-18	BOTOX® Cosmetic (onabotulinumtoxinA) Receives FDA Approval for Moderate to Severe Vertical Bands Connecting the Jaw and Neck (Platysma Bands)	CI
24-08-27	Allergan Aesthetics Announces the Launch of Its Next Generation Hydration Product: Skinmedica HA5 Hydra Collagen Replenish + Restore Hydrator	CI
24-06-27	Allergan Aesthetics Debuts Alle Payment Plans	CI

24-04-01	Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement	AQ
22-04-20	Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting	AQ
22-04-06	Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY 1.25% in Adults with Age-Related Blurry Near Vision	AQ
22-03-22	AbbVie and Allergan Aesthetics to Present New Research Across Dermatology Portfolio at 2022 AAD Annual Meeting	AQ
21-12-10	Allergan - VUITY 1.25%, the First and Only FDA-Approved Eye Drop to Treat Age-Related Blurry near Vision, is Now Available	AQ

21-04-20	Planète Bourse : La revue de presse du mardi 20 avril 2021
20-05-07	EN DIRECT DES MARCHES : Air France KLM, ArcelorMittal, Legrand, Natixis, Peugeot, Eurofins, Zalando, Facebook...
20-05-07	La Chine repart, mais Washington veille
20-05-06	EN DIRECT DES MARCHES : Danone, Sanofi, Crédit Agricole, Arkema, Neoen, Eurofins, BMW, Novo Nordisk...
20-05-06	Trump franchit le Rubicon

Actavis PLC Stock NYSE

Stocks

IE00BD1NQJ95

Pharmaceuticals

Valuation: Actavis PLC

Latest news : Actavis PLC

Press Releases: Actavis PLC

News in other languages: Actavis PLC

Managers and Directors: Actavis PLC

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Alex Thurman DFI	Director of Finance/CFO	56	2016-11-30
Robert Michael PSD	President	55	2020-05-07

Director	Title	Age	Since
Robert Michael BRD	Director/Board Member	55	2020-05-07
Scott Reents BRD	Director/Board Member	-	2020-05-07
Ryan Quigley BRD	Director/Board Member	-	2020-05-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-1.02%	+5.11%	+78.86%	+126.94%	1,119B
JOHNSON & JOHNSON	+1.25%	+4.37%	+53.49%	+65.87%	651B
ABBVIE INC.	+0.06%	+5.80%	+27.61%	+80.63%	468B
ROCHE HOLDING AG	-1.38%	+4.02%	+42.52%	+42.38%	374B
NOVARTIS AG	-0.52%	+2.72%	+25.21%	+41.06%	302B
ASTRAZENECA PLC	-1.06%	+4.76%	+2.00%	+12.65%	259B
AMGEN INC.	+0.60%	+5.26%	+53.03%	+72.02%	238B
NOVO NORDISK A/S	-0.53%	+2.34%	-18.53%	-53.66%	208B
GILEAD SCIENCES, INC.	+0.15%	+5.10%	+27.91%	+91.28%	181B
Average	-0.29%	+5.17%	+32.45%	+53.24%	422.21B
Weighted average by Cap.	-0.32%	+5.40%	+45.75%	+72.82%

	2018	2019
Net sales	15.79B 13.52B 12.65B 11.58B 21.74B 1,511B 22.03B 149B 58.3B 759B 59.28B 57.99B 2,510B	16.09B 13.78B 12.9B 11.8B 22.15B 1,539B 22.45B 152B 59.41B 773B 60.41B 59.1B 2,558B
Net income	-5.1B -4.37B -4.08B -3.74B -7.02B -488B -7.11B -48.26B -18.82B -245B -19.14B -18.72B -810B	-5.27B -4.52B -4.22B -3.87B -7.26B -504B -7.35B -49.91B -19.46B -253B -19.79B -19.36B -838B
Net Debt	21.89B 18.75B 17.55B 16.06B 30.14B 2,094B 30.54B 207B 80.84B 1,052B 82.2B 80.41B 3,480B	17.3B 14.82B 13.87B 12.7B 23.83B 1,656B 24.14B 164B 63.9B 832B 64.98B 63.56B 2,751B

End-of-day quote NYSE
- ^USD	-